DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
Pedro Cahn
REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.
